Al-Nbaheen M, Vishnubalaji R, Ali D, Bouslimi A, Al-Jassir F, Megges M, Prigione A, Adjaye J, Kassem M, Aldahmash A: Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential.  Stem Cell Rev 2013, 9:32-43.
Del Pino A, Ligero G, López MB, Navarro H, Carrillo JA, Pantoll SC, Díaz de la Guardia R. Morphology, cell viability, karyotype, expression of surface markers and plasticity of three human primary cell line cultures before and after the cryostorage in LN2 and GN2. Cryobiology. 2015 Feb;70(1):1-8.
Dimarino, A.M.; Caplan, A.I.; and Bonfield, T.L.: Mesenchymal Stem Cells in Tissue Repair. Front Immunol. 2013 Sep 4;4:201.
Filardo G, Madry H, Jelic M, Roffi A, Cucchiarini M, Kon E. Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics. Knee Surg Sports Traumatol Arthrosc 2013; 21:1717-1729.
Marigo I, Dazzi F. The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol. 2011;33:593–602.
Marta E. Castro-Manrreza, Juan J. Montesinos, Immunoregulation by Mesenchymal Stem Cells: Biological Aspects and Clinical Applications, Journal of Immunology Research, 2015, 2015, 1.
Medyouf, H., Mossner, M., Jann, J.C. et al, Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014;14:824–837.
Méndez-Ferrer S, Scadden DT, Sánchez-Aguilera A. Bone marrow stem cells: current and emerging concepts. Ann N Y Acad Sci. 2015 Jan; 1335(1):32-44.
Murphy MB, Moncivais K, & Caplan AI (2013) Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental & molecular medicine 45:e54.
Nardi, N. Beyer; da Silva Meirelles, L. (2006). "Mesenchymal Stem Cells: Isolation, In Vitro Expansion and Characterization". In Wobus, Anna M.; Boheler, Kenneth. Stem Cells. Handbook of experimental pharmacology 174. pp. 249–82.
Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, Wang CY (2013)The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 19: 35–42
C. Kim, “Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application,” Blood Research, vol. 49, no. 1, pp. 7–14, 2014.
Chang CW. et al., 2009. Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells. 27(5):1042-9.
D.-S. Kim, P. Joel Ross, K. Zaslavsky, and J. Ellis, “Optimizing neuronal differentiation from induced pluripotent stem cells to model ASD,” Frontiers in Cellular Neuroscience, vol. 8, no. 1, article 109, 2014.
Kaji K. et al., 2009. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature. 458(7239):771-5.
Kamata M. et al. 2010. Live cell monitoring of hiPSC generation and differentiation using differential expression of endogenous microRNAs. PLoS One. 5(7):e11834.
Kim D. et al., 2009. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 4(6):472-6.
Lin T. et al., 2009. A chemical platform for improved induction of human iPSCs. Nat Methods. 6(11):805-8.
Mallanna SK. & Rizzino A., 2010. Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells. Dev Biol. 344:16-25.
Okita K, Ichisaka T, Yamanaka S.  Generation of germline-competent induced pluripotent stem cells. Nature. 2007 Jul 19; 448(7151):313-7.
Sarkis C. et al., 2008. Non-integrating lentiviral vectors. Curr Gene Ther. 8(6):430-7. Review.
Shi Y et al., 2008b. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 2008 Nov 6;3(5):568-74.
Soldner F. et al., 2009. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 136(5):964-77.
Soria-Valles C, Osorio FG, Gutiérrez-Fernández A, De Los Angeles A, Bueno C, Menéndez P, Martín-Subero JI, Daley GQ, Freije JM, López-Otín C. NF-κB activation impairs somatic cell reprogramming in ageing. Nat Cell Biol. 2015 Aug;17(8):1004-13. doi: 10.1038/ncb3207. Epub 2015 Jul 27.
Takahashi K, Yamanaka S (2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors". Cell 126 (4): 663-676.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors". Cell 131 (5): 861-872.
Wan W, Cao L, Kalionis B, Xia S and Tai X. (2015) Applications of induced pluripotent stem cells in studying the neurodegenerative diseases. Review. Stem Cells International. In Press (accepted 9 Dec 2014)
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R et al (2007). "Induced pluripotent stem cell lines derived from human somatic cells". Science 318 (5858): 1917-1920.
Zhou H. et al., 2009. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 4(5):381-4. Catalina, P., Cobo, F., Cortes, J.L., Nieto, A.I., Cabrera, C., Montes, R., Concha, A., and Menendez, P. (2007). Conventional and molecular cytogenetic diagnostic methods in stem cell research: a concise review. Cell Biol Int 31, 861-869.
Catalina, P., Bueno, C., Montes, R., Nieto, A., Ligero, G., Sanchez, L., Jara, M., Rasillo, A., Orfao, A., Cigudosa, J., et al. (2009). Genetic stability of human embryonic stem cells: A first-step toward the development of potential hESC-based systems for modeling childhood leukemia. Leuk Res 33, 980-990.
Catalina, P., Montes, R., Ligero, G., Sanchez, L., de la Cueva, T., Bueno, C., Leone, P.E., and Menendez, P. (2008). Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties? Mol Cancer 7, 76.
Cortes, J.L., Sanchez, L., Catalina, P., Cobo, F., Bueno, C., Martinez-Ramirez, A., Barroso, A., Cabrera, C., Ligero, G., Montes, R., et al. (2008). Whole-blastocyst culture followed by laser drilling technology enhances the efficiency of inner cell mass isolation and embryonic stem cell derivation from good- and poor-quality mouse embryos: new insights for derivation of human embryonic stem cell lines. Stem Cells Dev 17, 255-267.
Catalina P; Montes R; Ligero G; Sanchez L; de la Cueva T; Bueno C; Leone PE; Menendez P. HumanESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerabilityamong hESC lines due to inherent properties?. Molecular Cancer. 2008. Disponible en Internet en:http://europepmc.org/abstract/med/18834512.
Catalina P; Cobo F; Cortés JL; Nieto AI; Cabrera C; Montes R; Concha A; Menendez P. Conventional andmolecular cytogenetic diagnostic methods in stem cell research: a concise review.Cell Biology International. 09/2007. Disponible en Internet en:http://europepmc.org/abstract/med/17467306
Jose Antonio Carrillo Ávila; Amanda De la Fuente Vazquez; Gertrudis Ligero Martín; Rocío Aguilar Quesada; Purificación Catalina Carmona. Development of a new sensitive real-time PCR technique Mollicutes in cell culture. BMC Medical Research Methodoly. BMC, 23/07/2020.
Carrillo Avila 1; Catalina Carmona 2; Aguilar Quesada 3. Quality Control of Cell Lines Using DNA as Target. DNA. 2 - 1, pp. 44 - 55. Academic Editor: Michael Fried, 16/02/2022.
Orden SCO/393/2006, del 8 de febrero, por la que se establece la organización y funcionamiento del Banco Nacional de Líneas Celulares.
Ley 14/2007 de Investigación Biomédica.
Real Decreto 1716/2011, de 18 de noviembre,por el que se establecen los requisitos básicos de autorización y funcionamiento de los biobancos con fines de investigación biomédica y del tratamiento de las muestras biológicas de origen humano, y se regula el funcionamiento y organización del Registro Nacional de Biobancos para investigación biomédica.
Decreto 1/2013 de 8 de enero, por el que se regula la autorización para la constitución y funcionamiento de Biobancos con fines de investigación en Andalucía y se crea el Biobanco del Sistema Sanitario Público de Andalucía.
Orden ECC/1404/2013, de 28 de junio,por el que se modifica el anexo del Real Decreto 1716/2011, de 18 de noviembre, por el que se establecen los requisitos básicos de autorización y funcionamiento de los biobancos con fines de investigación biomédica y del tratamiento de las muestras biológicas de origen humano, y se regula el funcionamiento y organización del Registro Nacional de Biobancos para investigación biomédica.
